Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Induction in myeloma: a journey over time

Mohamad Mohty • 15 Jun 2019
EHA 2019
Multiple Myeloma Bortezomib Carfilzomib Daratumumab Dexamethasone Isatuximab Thalidomide
CASSIOPEIA

Induction therapy regimens prior to transplant in multiple myeloma have changed significantly over the past several decades, as explained by Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France. Prof. Mohty gives us his insight into this change and where we may be going next. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Mohamad Mohty

5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024
4:02
Moving CAR-T therapy into earlier lines of treatment for myeloma and the need for effective bridging
Mohamad Mohty • 15 Feb 2024

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals